ConductScience.org, home

Paper40964320

General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants.

Tedman A and 12 others. bioRxiv, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants. Papers, record 40964320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40964320

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants.
PubMed
Journal
bioRxiv
PubMed
Year
2025
PubMed
Publication types
Journal Article, Preprint
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-16
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tedman AAustin
2Olson JA 3rdJohn A
3Kim MMinsoo
4Foye CCatherine
5Jackson JJJaNise J
6McDonald EFEli F
7McKee AGAndrew G
8Noguera KKaren
9Kuntz CPCharles P
10Meiler JJenshttps://orcid.org/0000-0001-8945-193X
11Oliver KKathrynhttps://orcid.org/0000-0002-7781-7006
12Plate LLars
13Schlebach JPJonathan Phttps://orcid.org/0000-0003-0955-7633

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
F31 HL162483NHLBI NIH HHSUnited StatesF31HL162483PubMed and NIHNIH RePORTER
R01 HL167046NHLBI NIH HHSUnited StatesR01HL167046PubMed and NIHNIH RePORTER
R35 GM133552NIGMS NIH HHSUnited StatesR35GM133552PubMedNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Updated in41379933General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants.https://conductscience.org/library/papers/41379933

Source PubMed

Download CSV of comments and corrections

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137730207CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.ACS Chem Biol2023https://conductscience.org/library/papers/37730207PubMed
233781744The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue.J Biol Chem2021https://conductscience.org/library/papers/33781744PubMed
311423120Green fluorescent protein-based halide indicators with improved chloride and iodide affinities.FEBS Lett2001https://conductscience.org/library/papers/11423120PubMed
418716059
Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2.
Mol Biol Cell2008https://conductscience.org/library/papers/18716059PubMed
535327663Structural Comparative Modeling of Multi-Domain F508del CFTR.Biomolecules2022https://conductscience.org/library/papers/35327663PubMed
628335006A platform for functional assessment of large variant libraries in mammalian cells.Nucleic Acids Res2017https://conductscience.org/library/papers/28335006PubMed
729099344Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.N Engl J Med2017https://conductscience.org/library/papers/29099344PubMed
815923638Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin.Mol Cell Biol2005https://conductscience.org/library/papers/15923638PubMed
927168400Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.PLoS Biol2016https://conductscience.org/library/papers/27168400PubMed
1027660821Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases.JCI Insight2016https://conductscience.org/library/papers/27660821PubMed
1138388235In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.J Cyst Fibros2024https://conductscience.org/library/papers/38388235PubMed
1240261935Proteostasis landscapes of cystic fibrosis variants reveal drug response vulnerability.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/40261935PubMed
1319307599N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic.J Cell Biol2009https://conductscience.org/library/papers/19307599PubMed
1433468668Positive epistasis between disease-causing missense mutations and silent polymorphism with effect on mRNA translation velocity.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/33468668PubMed
1539388263Ribosomal frameshifting selectively modulates the assembly, function, and pharmacological rescue of a misfolded CFTR variant.Proc Natl Acad Sci U S A2024https://conductscience.org/library/papers/39388263PubMed
1637253358General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants.Cell Chem Biol2023https://conductscience.org/library/papers/37253358PubMed
1732285592Calnexin cycle - structural features of the ER chaperone system.FEBS J2020https://conductscience.org/library/papers/32285592PubMed
1837690692Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics.J Biol Chem2023https://conductscience.org/library/papers/37690692PubMed
1926676362N-Glycan-based ER Molecular Chaperone and Protein Quality Control System: The Calnexin Binding Cycle.Traffic2016https://conductscience.org/library/papers/26676362PubMed
2035389766Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants.Mol Biol Cell2022https://conductscience.org/library/papers/35389766PubMed

See all 40 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CANX821PubTator's text mininghttps://conductscience.org/library/genes/821NCBI Gene
CFTR1080PubTator's text mininghttps://conductscience.org/library/genes/1080NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40964320

GET https://conductscience.org/api/papers/v1/40964320/references?page=2